- Home
- CBNA vs DERM Comparison
CBNA vs DERM Comparison
Compare CBNA & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- DERM
- Stock Information
- Founded
- CBNA 2006
- DERM 2014
- Country
- CBNA United States
- DERM United States
- Employees
- CBNA N/A
- DERM N/A
- Industry
- CBNA
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- CBNA
- DERM Health Care
- Exchange
- CBNA NYSE
- DERM Nasdaq
- Market Cap
- CBNA 159.8M
- DERM 181.0M
- IPO Year
- CBNA 2024
- DERM 2021
- Fundamental
- Price
- CBNA $26.60
- DERM $7.10
- Analyst Decision
- CBNA Buy
- DERM Strong Buy
- Analyst Count
- CBNA 3
- DERM 2
- Target Price
- CBNA $29.67
- DERM $10.00
- AVG Volume (30 Days)
- CBNA 31.8K
- DERM 178.0K
- Earning Date
- CBNA 08-15-2025
- DERM 08-11-2025
- Dividend Yield
- CBNA N/A
- DERM N/A
- EPS Growth
- CBNA 60.12
- DERM N/A
- EPS
- CBNA 4.10
- DERM N/A
- Revenue
- CBNA $57,087,000.00
- DERM $56,243,000.00
- Revenue This Year
- CBNA N/A
- DERM $28.99
- Revenue Next Year
- CBNA $17.50
- DERM $52.61
- P/E Ratio
- CBNA $6.49
- DERM N/A
- Revenue Growth
- CBNA 62.88
- DERM N/A
- 52 Week Low
- CBNA $20.01
- DERM $3.54
- 52 Week High
- CBNA $27.97
- DERM $8.25
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- DERM 52.70
- Support Level
- CBNA N/A
- DERM $6.63
- Resistance Level
- CBNA N/A
- DERM $7.28
- Average True Range (ATR)
- CBNA 0.00
- DERM 0.38
- MACD
- CBNA 0.00
- DERM 0.03
- Stochastic Oscillator
- CBNA 0.00
- DERM 83.02
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.